Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of information unless it contains a valid OMB control number

				Complete if Known		
Substitute fo	r form 144	9/PTO		Application Number	10/714,078	
INFORM	IATION	DISCL	OSURE	Filing Date	November 14, 2003	
STATEM				First Named Inventor	Gunars Valkirs	
(Use as	many shee	s as neces	sary)	Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	1	Of	7	Attorney Docket Number	36671-743.503	

		U.S. P.	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0052000 A1	05/02/2002	Parthasarathy et al.	
	2.	US 2002/0106708 A1	08/08/2002	Thomas et al.	
	3.	US 2003/0119064 A1	06/26/2003	Valkirs et al.	
	4.	US 2003/0199000 A1	10/23/2003	Valkirs et al.	
	5.	US 2003/0211544 A1	11/13/2003	Buechler et al.	
	6.	US 2003/0219734 A1	11/27/2003	Buechler	
	7.	US 2004/0121343 A1	06/24/2004	Buechler et al.	
	8.	US 2004/0121350 A1	06/24/2004	Anderberg et al.	
	9.	US 2004/0126767 A1	07/01/2004	Anderberg et al.	
	10.	US 2004/0171064 A1	09/02/2004	Dahlen et al.	
	11.	US 2004/0176914 A1	09/09/2004	Buechler et al.	
	12.	US 2004/0203083 A1	10/14/2004	Buechler et al.	
	13.	US 2004/0209307 A1	10/21/2004	Valkirs et al.	
	14.	US 2004/0253637 A1	12/16/2004	Buechler et al.	
	15.	US 2005/0148024 A1	07/07/2005	Buechler	
	16.	US 2005/0164317 A1	07/28/2005	Buechler et al.	
	17.	US 2005/0255484 A1	11/17/2005	Valkirs et al.	
	18.	US 2006/0051825 A1	03/09/2006	Buechler et al.	
	19.	US 2006/0105419 A1	05/18/2006	Blankenberg et al.	
	20.	US 2007/0092911 A1	04/26/2007	Buechler et al.	
	21.	US 2007/0196880 A1	08/23/2007	Buechler et al.	
	22.	US 2007/0218498 A1	09/20/2007	Buechler et al.	
	23.	US 2007/0224643 A1	09/27/2007	Mcpherson et al.	
	24.	US 2007/0269836 A1	11/22/2007	Mcpherson	

Examiner	Date
Signature	Considered

Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signature | Signat

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE a collection of information unless it contains a valid OMB control number

				Con	nplete if Known
Substitute fo	or form 1449	/PTO		Application Number	10/714,078
INFORM	IATION I	DISC	LOSURE	Filing Date	November 14, 2003
	MENT BY			First Named Inventor	Gunars Valkirs
(Use as	many sheets	s as ne	cessary)	Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	2	Of	7	Attorney Docket Number	36671-743.503

		U.S. P.	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	25.	US 2008/0045444 A1	02/21/2008	Whittaker	
	26.	US 2008/0118924 A1	05/22/2008	Buechler	
	27.	US 4,900,662	02/13/1990	Shah et al.	
	28.	US 5,202,234	04/13/1993	Shah et al.	
	29.	US 5,382,515	01/17/1995	Shah et al.	
	30.	US 5,382,522	01/17/1995	Shah et al.	
	31.	US 5,482,935	01/09/1996	Adelman et al.	
	32.	US 5,683,885	11/04/1997	Kieback	
	33.	US 5,795,725	08/18/1998	Buechler et al.	
	34.	US 5,814,462	09/29/1998	Weinberger	
	35.	US 5,843,690	12/01/1998	Gargan	
	36.	US 6,156,521	12/05/2000	Buechler et al.	
	37.	US 6,174,686 B1	01/16/2001	Buechler et al.	
	38.	US 6,495,519 B1	12/17/2002	He et al.	
	39.	US 6,579,687 B1	06/17/2003	Buechler et al.	
	40.	US 6,627,404 B1	09/30/2003	Buechler et al.	
	41.	US 6,939,678 B1	09/06/2005	Buechler et al.	
	42.	US 6,991,907 B1	01/31/2006	Buechler et al.	
	43.	US 7,341,838 B2	03/11/2008	Buechler et al.	
	44.	US 7,358,055 B2	04/15/2008	Valkirs et al.	
	45.	US 7,361,473 B2	04/22/2008	Valkirs et al.	
	46.	US 7,427,490 B2	08/20/2002	Valkirs	

Examiner Date		
	Examiner	
		Considered

Exchange It is a series of the part of the properties of the part of the properties of the part of the

check rock her if Fagible Braguage Transition is attained.

The Collection of information is required by TCX, 197 and 198. The lithermation is required to obtain or ration a baseful by the public whech is to fife (and by the USFTO to process) an application. Confidentially is governed by 5 USA. 122 and 37 CFR. 114. This collection is relationable to the 2-hours to ecopylate, landering gathering preparing, and informating the remarkable of the public which is provided by the Confidential Confide

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE a surface it contains a sulid OMD control number

				Con	nplete if Known
Substitute fo	or form 1449	/PTO		Application Number	10/714,078
INFORM	IATION I	DISC	LOSURE	Filing Date	November 14, 2003
STATEM	IENT BY	APP	LICANT	First Named Inventor	Gunars Valkirs
(Use as	many sheets	as ne	cessary)	Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	3	Of	7	Attorney Docket Number	36671-743.503

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	No.1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (If Insum)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°	
	47.	WO 1998/043630 A1	08/10/1998	Ridker et al.			
	48.	WO 2001/042793 A2	06/14/2001	Hochstrasser et al.			
	49.	WO 2004/058055 A2	07/15/2004	Anderberg et al.			
	50.	WO 2004/094459 A2	11/04/2004	Buechler			
	51.	WO 2004/094460 A2	11/04/2004	Buechler et al.			

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, eity and/or country where published.				
	52.	ANDERSON, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physiol. 563.1; 2004: 23-60.				
	53.	BARBER, et al. Hemostatic function and progressing ischemic stroke: D-dirner predicts early clinical progression. Stroke. 2004 Jun;35(6):1421-5. Epub 2004 Apr 8.				
	54.	BIDZSERANOVA, et al. Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats. Neuropeptides, 1992;23(2), 61-65.				
	55.	BREYER, J. dissenting. Supreme Court of The United States, No. 04-607. Laboratory Coproration of America Holdings, DBA Laborap, Petitioner v. Metabolite Laboratories, Inc., et al. June 22, 2006 (slip opinion) pages 1-15.				
	56.	CARVILLE, et al. Thrombus precursor protein (TpPTM): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin. Chem. 1996;42:1537-1541.				
	57.	CHANG, et al. C-Reactive Protein Binds to Both Oxidized LDL and Apototic Cells Through Recognition of a Common Ligand; Phosphorylcholine of Oxidized Phospholipids.				

Examiner Date Signature Considered			
	Examiner	Date	
	Signature	Considered	

Signifiation

Si

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it contains a valid OMB control number. Under the paperwork Reduction Act of 1995, no persons required to respo

				Complete if Known		
Substitute fo	r form 1449	/PTO		Application Number	10/714,078	
INFORM	IATION I	DISCI	OSURE	Filing Date	November 14, 2003	
STATEM				First Named Inventor	Gunars Valkirs	
(Use as many sheets as necessary)		Art Unit	1641			
				Examiner Name	Lisa V. Cook	
Sheet	4	Of	7	Attorney Docket Number	36671-743.503	

		NON BATTENEL LINED ATWIND DOCUMENTS
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), tille of the raticle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	CHOUDHRI, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999 Jul 5;190(1):91-9.
	59.	CHRISTENSON, et al. Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. Clin Chem. 2001 Mar,47(3):431-7.
	60.	CLARK, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997 Nov 28;238(1-2):53-6.
	61.	COEROLI, et al. Nitric oxide production and perivascular tyrosine nitration following focal ischemia in neonatal rat. J Neurochem. 1998 Jun;70(6):2516-25.
	62.	COSSINS, et al. Enhanced Expression of MMP-7 and MMP-9 in Demyelinating Multiple Sclerosis Lesions. Acta. Neuropathol. 1997;94:590-598.
	63.	DE MEESTER, et al. In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). Biochem Pharmacol. 1997 Jul 1;54(1):173-9.
	64.	EIKELBOOM, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.
	65.	FASSBENDER, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1944 Apr;122(2):135-9.
	66.	FUKUI, et al. Focal Brain Edema and Natriuretic Peptides in Patients with Subarachnoid Hemorrhage. J. of Clin. Neuroscience. 2004;11(5): 507-511.
	67.	HARRINGTON, J.R. The Role of MCP-1 in Atherosclerosis. Stem Cells. 2000;18: 65-66.

Examiner						Т	Date		Т					\neg
Signature						П	Consi	dered	1					

EXAMINEE: Initial if reference considered, whether or no citation is in conformance with MPP 009. Then line through citation if not in conformance and not considered. Include coay of his form with sent constructions to applicate. Applicant is value critation designation number (optional). Beer finding code of USPTO Parts Decument as www.napsp.gov.or.MPP 100.1 % Earth Citation is final and the choncurs, by the venders code (WISPTO Sente Decument as www.napsp.gov.or.MPP 100.1 % Earth Citation is final and the choncurs in the venders code (WISPTO Sente Sente Decument as www.napsp.gov.or.MPP 100.1 % Earth Citation in the law and the choncurs in the venders code (WISPTO Sente Sente Decument as www.napsp.gov.or.MPP 100.1 % Earth Citation in the law and the choice and the law in the confidence of the parts of the contract in the confidence of the parts of the contract in the confidence of the parts of the contract in the confidence of the parts of the contract in the confidence of the parts of the contract in the

clocks much here if Beginh language Treatments nationally and 186. The information is required to obtain or entire a benefit by the police which is to the (and by the USPTO to process) an Electronic for the collectron of effective in required to obtain or entire a benefit by the police which is to the (and by the USPTO to process) an Electronic formation of the USPTO formation of the control of the USPTO formation of the information of the USPTO formation of the information of the USPTO formation of

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known				
Substitute fo	or form 144	9/PTO		Application Number	10/714,078			
INFORM	IATION	DISCL	OSURE	Filing Date	November 14, 2003			
STATEM	MENT B	Y APPL	ICANT	First Named Inventor	Gunars Valkirs			
(Use as	many shee	ets as neces	ssary)	Art Unit	1641			
				Examiner Name	Lisa V. Cook			
Sheet	5	Of	7	Attorney Docket Number	36671-743.503			

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LEITRES), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	68.	HATFIELD, et al. CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res. 1992 Apr 17;577(2):249-52. (abstract only)
	69.	HEESCHEN, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.
	70.	International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.
	71.	International Search Report dated 10/20/2004 for PCT Application No. US04/26984.
	72.	KANEKO, et at., Circulating levels of β -chemokines in systemic lupus erythematosus. J. Rheumatol. 26:568-573, 1999.
	73.	KLINE, et al. New diagnostic tests for pulmonary embolism. Ann Emerg Med. 2000 Feb;35(2):168-80.
	74.	LESCUYER, et al. Identification of Post-Mortem Cereberal Spinal Fluid Proteins as Potential Biomarkers of Ischemia and Neurodegeneration. Proteomics. 2004;(4): 2234-2241.
	75.	LINDON, J. C. Biomarkers: Present concepts and future promise. Preclinica. 2003;1: 221.
	76.	LIP, et al. Von Willebrand Factor and Its Relevance to Cardiovascular Disorders. Br Heart J. 1995;74:580-583.
	77.	MA, et al. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res. 2003 Mar 21;966(2):167-74.
	78.	Management of the patient with stroke. Chapter One - Trends in stroke prevention and management. Available at: http://69.3.158.146/nurse/courses/nurseweek/NW0200/c1/p01.htm

Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.		y
of this form with next communication to applicant. Applicant's unique citation designation number (options		
901 04 3 Finter Office that issued the document by the barnletter code (WIPO Standard ST 1) 4 for famous		

Date

of this form with next communication to appreciat. Applicant is unique citation designation insurface (optional). See Kinde Codes of USFTO Pinest Documents at vew upon gary or MMFP 19 14. The Code of the control is a small code. If you have a first a proper panel of control, the individual of the your of the regist of the integer state. If you have a first a proper panel of control is the individual of the your of the regist of the integer state. If you have a first a proper panel of control is the individual of the your first and the proper panel of the proper panel pa

Examiner

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid QMB control number. Under the paperwork Reduction Act of 1995, no persons required to re-

				Complete if Known				
Substitute fe	or form 144	9/PTO		Application Number	10/714,078			
INFORM	IATION	DISC	LOSURE	Filing Date	November 14, 2003			
STATEM	ENT BY	APP	LICANT	First Named Inventor	Gunars Valkirs			
(Use as	many sheet	s as nec	essary)	Art Unit	1641			
				Examiner Name	Lisa V. Cook			
Sheet	6	Of	7	Attorney Docket Number	36671-743.503			

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	79.	McGIRT, et al. Serum Von Willebrand Factor, Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor Levels Predict the Onset of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrage. Neurosurgery. 2002;51(5):1128-1135.
	80.	Office Action from Japanese Patent Office dated 06/10/2008 for Japanese Application No. JP2003-521366 (in Japanese with English translation).
	81.	ORBE, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis 2007;5 (1), 91–97.
	82.	RUS, et al. Interleukin-6 and Interleukin-8 protein and Gene Expression in Human Arterial Atheroslcerotic Wall. Atheroslcerosis. 1996;127:263-271.
	83.	SHIRASAKI, et al. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res. 2004 Sep 24;1021(2):159-66.
	84.	STANEK, et al. Prognostic Evaluation of Neurohumoral Plasma Levels Before and During Beta Blocker Therapy in Advanced Left Ventricular Dysfunction. JACC. 2002;38(2): 436-442.
	85.	TAKEBAYASHI, et al. Association between circulating monocyte chemoattractant protein-1 and urnary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications. 2006 Mar-Apr.20(2):98-104.
	86.	TOMIDA, et al. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998 Aug;29(8):1584-7.
	87.	UCHIYAMA et al., Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke, Semin. Thromb. Hemost. 23: 535-541 (1997).
	88.	VASAN, et al. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hyperthrophy and Systolic Dysfunction. JAMA. 2002;288(10): 1252-1259.

Examiner	Date	
Signature	Considered	

^{**}EXAMINE.** Initial reference continent, whether or not extent in a conformance with MFE (OR. Exer for already about of an is undermose and see considered, whether of a resident in a conformance with MFE (OR. Exer for already) about of a southernoon and see considered in the conformance with the confo

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known					
Substitute f	or form 144	9/PTO		Application Number	10/714,078				
INFORM	IATION	DISC	LOSURE	Filing Date	November 14, 2003				
STATE	MENT BY	APP	LICANT	First Named Inventor	Gunars Valkirs				
(Use a	s many shee	ts as nee	essary)	Art Unit	1641				
				Examiner Name	Lisa V. Cook				
Sheet	7	Of	7	Attorney Docket Number	36671-743.503				

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	89.	VASAN, R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16;113(19):2335-62.						
	90.	ZHOU, et al. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem Biophys Res Commun. 2003 Sep 19;309(2):368-76.						
	91.	ZWEIG, et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561-77.						

Examiner	Date
Signature	Considered

Explainable: Initial If reference considered, whether or not clustion is in conformance with MPEP 699. Durw line through clustion if not in conformance and not considered. Include copy of this time with next communication in applicant. Applicant is subspice action in agreement in market (partial). The reliable conformation is applicant. Applicant is subspice action in agreement in market (partial). The first include of the SPEP 0 Partial Documents as were supplied or the partial includes of the SPEP 0 Partial Documents as were supplied or the partial includes of the SPEP 0 Partial Documents as were supplied and the partial includes of the special partial partial